查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008668

子宫内避孕器市场：按产品类型、使用时长、销售管道和最终用户分類的全球市场预测 – 2026-2032 年

Intrauterine Devices Market by Device Type, Usage Duration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，子宫内避孕器 (IUD) 市值将达到 33.7 亿美元，到 2026 年将成长至 35 亿美元，到 2032 年将达到 49.6 亿美元，复合年增长率为 5.68%。

主要市场统计数据
基准年 2025 33.7亿美元
预计年份：2026年 35亿美元
预测年份 2032 49.6亿美元
复合年增长率 (%) 5.68%

本报告对避孕器）在现代避孕策略中的作用进行了清晰权威的概述，并阐述了本报告的分析方法和价值。

子宫内避孕器（IUD）是现代避孕策略的基石，它提供长效且可逆的避孕效果，符合不断变化的患者偏好和临床指南。围绕这些技术的格局已不再局限于简单的铜製与激素二元对立，而是涵盖了装置设计、放置技术和术后护理通讯协定等方面的进步。临床医生、保险公司和製造商都必须应对日益复杂的临床证据、监管、供应链趋势和以患者为中心的服务模式之间的相互作用。

对技术创新、监管重点以及不断变化的患者和医疗保健提供者的偏好如何重塑子宫内避孕器(避孕器)的引入和使用进行详细分析。

子宫内避孕器（避孕器）的现状正经历着变革，这主要得益于技术进步、临床指南的更新以及患者期望的转变。荷尔蒙配方和节育器形状的创新正在延长放置时间窗口并提高耐受性。此外，临床医师对产后和青少年放置节育器的理解不断加深，也扩大了适用人群。同时，远端医疗和数位化服务的进步正在重塑放置前咨询和追踪流程，从而建立以患者为中心的模式，减轻诊所的负担并提高患者对建议追踪计画的依从性。

评估 2025 年的关税环境以及贸易政策变化对避孕器(IUD) 供应链的韧性、采购选择和临床可用性的影响。

2025年关税的实施和贸易政策的调整为整个子宫内避孕器供应链带来了新的变数，影响了製造成本、分销计划和筹资策略。进口零件和原材料的关税增加了部分製造商的单位投入成本，促使他们采取短期应对措施，例如与供应商重新谈判合约、策略性地增加库存以及选择性地转移某些生产活动。这些供应侧的调整凸显了弹性筹资策略的重要性，这些策略需要平衡成本、前置作业时间和品质保证要求。

透过对设备类型、通路、临床环境和计画使用週期进行详细的細項分析，可以製定有针对性的策略和营运方案。

分析细分市场层面的趋势揭示了医疗器材采纳和采购过程中存在的细微因素，这些因素会因医疗设备的特性、通路、终端用户环境和预期使用寿命而异。根据医疗设备的产品类型，铜製器械和激素类器械的市场研究是分开进行的。这种区分仍然是临床咨询和产品选择的关键决定因素，因为它对应着不同的副作用、非避孕益处以及对荷尔蒙过敏患者的适用性。当需要避免使用荷尔蒙或月经管理并非主要考虑因素时，铜製器械仍然是首选。另一方面，寻求减少出血或月经益处的患者通常更倾向于选择荷尔蒙类器械。

详细的区域分析表明，基础设施、报销制度和文化因素如何独特地影响子宫内避孕器( IUD) 的分销和商业性方法。

子宫内避孕器（ IUD）的使用和商业策略的区域趋势反映了医疗基础设施、报销标准以及对避孕的文化态度方面的差异。在美洲，长效可逆避孕法正日益融入妇科和产科的常规工作流程，尤其註重产后放置，并扩大了医护人员的培训计画。该地区的需求模式受到公共和私人保险公司、都市区医疗服务获取差异以及影响医疗系统层面覆盖范围和采购的积极政策辩论等因素的影响。

对竞争定位进行策略概述，阐述临床证据、医疗保健专业人员的支持和经销伙伴关係如何塑造避孕器(IUD) 领域的长期领导地位。

领先的医疗器材製造商与新兴挑战者之间的竞争格局日益取决于临床差异化、分销灵活性以及对循证医学的投入。那些兼具明确临床优势、可靠的上市后数据以及强大的医疗专业人员支援计画的公司，通常能够更深入地融入医疗服务系统。与药房、医院系统和培训联盟建立策略合作伙伴关係，有助于解决与植入技术、库存管理和患者追踪相关的实际障碍，从而促进产品的推广应用。

製造商和相关人员提出切实可行的、有影响力的建议，以增强供应链韧性、证据生成、临床医生培训以及患者跨渠道获取医疗服务。

产业领导者应优先采取一系列切实有效的措施，以维持市场准入、维护临床信任并打造差异化价值提案。首先，应透过多元化零件采购管道并确保检验的替代供应商，增强价值链韧性，从而减轻关税相关干扰和其他供应链中断的影响。除了这种营运柔软性之外，还应制定清晰的监管蓝图，对替代製造地和原材料进行认证，以避免临床供应缺口。

对调查来源、证据检验和调查方法进行透明的解释，以整合子宫内避孕器的临床、监管和供应链见解。

本分析基于多方面的研究途径，整合了同行评审的临床文献、监管申报文件、医疗设备附加檔、临床专家访谈以及对供应链和政策趋势的系统性回顾。临床研究结果是基于随机对照试验、观察性队列研究和纵向安全性註册研究，这些研究均经过调查方法严谨性和与当代临床实践相关性的评估。监管文件，包括核准文件和上市后监控总结，均经过仔细审查，以识别影响产品生命週期管理的新兴合规趋势和安全讯号。

简明结论整合了临床进步、供应韧性和有针对性的市场策略如何共同决定避孕器(IUD) 的未来供应和市场定位。

避孕器（IUD）目前正处于一个转折点，临床创新、不断发展的医疗服务模式以及贸易政策因素在此交汇，既带来了机会，也带来了挑战。技术进步和临床接受度的提高，尤其是在产后即刻和青春期放置方面，正使这些装置在综合生殖健康策略中发挥越来越重要的作用。同时，供应链对关税和零件采购的脆弱性凸显了营运弹性以及製造、监管和采购部门之间更紧密协调的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：子宫内避孕器市场：依器械类型划分

  • 由铜製成
  • 荷尔蒙药物

第九章：依使用时长分類的子宫内避孕器市场

  • 5年或以上
  • 3-5年
  • 不到3年

第十章：子宫内避孕器市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十一章：子宫内避孕器市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章：子宫内避孕器市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：子宫内避孕器市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：子宫内避孕器市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国子宫内避孕器市场

第十六章：中国子宫内避孕器市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • BioFem Therapeutics, LLC
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CooperCompanies, Inc.
  • Gedeon Richter Plc.
  • Medicines360, Inc.
  • Meril Life Sciences Pvt. Ltd.
  • Mona Lisa NV
  • Mylan NV by Viatris Inc.
  • Novartis AG
  • Ocon Medical Ltd
  • Pregna International Ltd.
  • Prosan International BV
  • Searchlight Pharma Inc.
  • Shenzhen Salubris Pharmaceuticals Co., Ltd.
Product Code: MRR-8E22B61932AA

The Intrauterine Devices Market was valued at USD 3.37 billion in 2025 and is projected to grow to USD 3.50 billion in 2026, with a CAGR of 5.68%, reaching USD 4.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.37 billion
Estimated Year [2026] USD 3.50 billion
Forecast Year [2032] USD 4.96 billion
CAGR (%) 5.68%

A clear and authoritative introduction situating intrauterine devices within modern contraceptive strategy and outlining the report's analytical approach and value

Intrauterine devices represent a cornerstone of modern contraceptive strategy, offering long-acting, reversible protection that aligns with evolving patient preferences and shifting clinical guidelines. The landscape surrounding these technologies has broadened beyond a simple copper versus hormonal dichotomy to encompass advances in device design, insertion techniques, and post-insertion care protocols. Clinicians, payers, and manufacturers alike must navigate an increasingly complex interplay of clinical evidence, regulatory scrutiny, supply chain dynamics, and patient-centered access models.

This executive summary synthesizes cross-cutting developments that are redefining how intrauterine devices are perceived, selected, and delivered across care settings. It situates recent technological refinements within real-world adoption patterns and operational constraints, highlighting the implications for training, procurement, and stakeholder communications. Readers will find a focused narrative that connects clinical efficacy and safety considerations to pragmatic commercial and policy questions, thereby enabling more informed decisions about product portfolios, distribution partnerships, and provider engagement strategies.

The following sections move from high-level shifts and policy impacts to granular segmentation and regional nuances, culminating in prescriptive recommendations and an accessible explanation of the research methods underpinning the analysis. Each element prioritizes clarity and applicability so that health system leaders, device manufacturers, and commercial strategists can translate insight into measurable actions.

A detailed exploration of how technological innovation, regulatory focus, and evolving patient and care delivery preferences are reshaping intrauterine device adoption and use

The landscape for intrauterine devices is undergoing transformative shifts driven by technological refinement, evolving clinical guidelines, and changing patient expectations. Innovations in hormonal formulations and device geometries are expanding insertion windows and improving tolerability, while growing clinician familiarity with immediate postpartum and adolescent insertion is broadening the pool of appropriate candidates. At the same time, advances in telehealth and digital engagement have reconfigured pre-insertion counseling and follow-up pathways, enabling more patient-centered models that reduce clinic burden and increase adherence to recommended follow-up schedules.

Concurrently, regulatory attention to safety surveillance and post-market studies has intensified, prompting manufacturers to invest more heavily in real-world evidence generation. This emphasis on longitudinal safety monitoring has elevated the importance of traceability, device registries, and harmonized adverse event reporting processes. Procurement and distribution models are shifting as well: centralized hospital purchasing is coexisting with an expansion of online pharmacy fulfillment and a renewed focus on ensuring continuity of supply for outpatient settings. These distribution shifts are altering commercial dynamics and reshaping the nature of partnerships between manufacturers, pharmacies, and provider organizations.

Importantly, patient preferences are changing; there is a stronger demand for reversible, long-acting contraception that minimizes systemic side effects and fits diverse reproductive plans. This has intensified investment in product differentiation and patient education initiatives, as manufacturers and providers seek to match device attributes to individual needs. The combined effect of technological, regulatory, and behavioral change is a market that rewards clinical evidence, ease of use, and access, and that penalizes slow adaptation to new care delivery models.

An assessment of the 2025 tariff environment and how trade policy changes are affecting supply chain resilience, procurement choices, and clinical availability of intrauterine devices

The imposition of tariffs and trade policy adjustments in 2025 has introduced a new variable that affects manufacturing costs, distribution planning, and procurement strategies across the intrauterine device supply chain. Tariffs on imported components and raw materials have raised unit input costs for some manufacturers, prompting near-term operational responses such as renegotiated supplier contracts, strategic inventory build-up, and selective relocation of certain manufacturing activities. These supply-side adjustments underscore the importance of a flexible procurement strategy that balances cost, lead time, and quality assurance requirements.

From a distribution perspective, tariffs have encouraged greater attention to sourcing diversification and to the feasibility of onshoring critical manufacturing steps. Health systems and purchasing organizations are reassessing supplier risk profiles and contingency plans to mitigate disruptions. Regulatory timelines for certifying relocated manufacturing lines or alternative component suppliers can introduce delays, requiring proactive engagement with authorities to validate equivalence and maintain continuity of supply.

Clinicians and provider networks may experience practical impacts in the form of changes to product assortments and availability at the point of care, which necessitates clearer communication with patients about device options. Procurement teams should evaluate long-term contracts and consider multi-sourcing strategies that preserve clinical choice while managing exposure to tariff-related cost volatility. In sum, the 2025 tariff environment necessitates a strategic response that integrates supply chain resilience, regulatory planning, and transparent stakeholder communication to sustain access and protect clinical continuity.

A granular segmentation analysis connecting device type, distribution pathway, clinical setting, and intended duration to inform targeted strategy and operational alignment

Segment-level dynamics reveal nuanced drivers of adoption and procurement that vary by device characteristics, distribution pathways, end-user environments, and intended duration of use. Based on Device Type, market is studied across Copper and Hormonal, and this distinction remains a primary determinant of clinical counseling and product selection because it aligns with differing side-effect profiles, non-contraceptive benefits, and suitability for patients with hormone sensitivities. Copper devices continue to appeal where hormone avoidance is desired and where menstrual management is less of a primary concern, while hormonal devices are often prioritized for patients seeking lighter bleeding patterns and amenorrhea-related benefits.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, and each channel has unique implications for stock management, reimbursement navigation, and patient access models. Hospital pharmacies typically support immediate postpartum and inpatient insertion workflows and therefore prioritize on-hand availability and established clinician relationships. Online pharmacies are reshaping pre-procedure counseling and device procurement by facilitating remote ordering and discreet fulfillment, while retail pharmacies play a critical role in outpatient continuity and often bridge the gap between clinician recommendation and patient procurement.

Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, and the choice of end-user setting influences procedural protocols, training requirements, and device preference. Ambulatory surgical centers often emphasize efficiency and predictable device selection to streamline throughput, hospitals must balance inventory for both inpatient and outpatient insertion needs, and specialty clinics may focus on high-touch counseling and complex case management. Based on Usage Duration, market is studied across Over Five Years, Three To Five Years, and Under Three Years, and duration categories are central to product positioning, warranty and reimbursement conversations, and patient counseling. Long-duration devices align with goals of minimal maintenance and sustained efficacy, whereas shorter-duration options can appeal to patients seeking more frequent fertility planning or those trialing device tolerance.

Taken together, these segmentation lenses provide a framework for aligning clinical value propositions with distribution capabilities and end-user workflow requirements. Manufacturers and providers can leverage these insights to tailor messaging, optimize inventory placement, and design training that maps device attributes to specific clinical and operational contexts.

An in-depth regional synthesis showing how infrastructure, reimbursement frameworks, and cultural factors uniquely influence intrauterine device adoption and commercial approaches

Regional dynamics in intrauterine device utilization and commercial strategy reflect divergent healthcare infrastructures, reimbursement norms, and cultural attitudes toward contraception. In the Americas, clinical practice increasingly integrates long-acting reversible contraception into both routine gynecologic care and obstetric workflows, with a focus on immediate postpartum insertion and expanding provider training programs. Demand patterns in this region are shaped by a mix of public and private payers, variable access across rural and urban settings, and active policy discussions that influence coverage and procurement at the health system level.

In Europe, Middle East & Africa, the landscape is heterogeneous: established European markets emphasize rigorous post-market surveillance and incremental device innovation, while healthcare systems in parts of the Middle East and Africa face access constraints that prioritize cost-effective, robust supply chains and simplified training protocols. Stakeholders in this region must navigate a wide spectrum of regulatory pathways and health system maturity levels, which prompts differentiated commercial approaches that combine capacity building with targeted distribution partnerships.

In Asia-Pacific, growth in clinician training, increased awareness of long-acting contraceptive benefits, and expansion of outpatient care models are notable. Diverse regulatory environments and variations in public procurement mechanisms mean manufacturers often pursue country-specific strategies that address local reimbursement practices and cultural considerations regarding family planning. Across all regions, the interplay between urbanization, digital health adoption, and provider training programs is reshaping how devices are recommended, procured, and supported clinically, making regional customization a necessary component of effective market engagement.

A strategic overview of competitive positioning showing how clinical evidence, provider enablement, and distribution partnerships shape long-term leadership in the intrauterine device sector

Competitive dynamics among leading device makers and emerging challengers are increasingly defined by clinical differentiation, distribution agility, and investments in evidence generation. Firms that pair clear clinical advantages with robust post-market data and strong provider support programs generally achieve deeper integration into care pathways. Strategic alliances with pharmacies, hospital systems, and training consortia strengthen adoption by addressing practical barriers related to insertion competency, inventory management, and patient follow-up.

New entrants and niche players are focusing on distinct value propositions such as simplified insertion systems, reduced hormone exposure profiles, or novel materials designed to enhance tolerability. Established manufacturers respond by broadening educational outreach, expanding clinician training programs, and leveraging real-world data to substantiate safety and patient satisfaction claims. The competitive landscape therefore rewards a balanced approach that combines product-level innovation with meaningful investments in provider enablement and supply chain robustness.

Partnership models that integrate manufacturers with distribution networks and clinical training providers create durable advantages, particularly when they reduce time-to-provision for immediate postpartum insertions and outpatient procedures. Intellectual property portfolios remain relevant but are only one element of competitiveness; the ability to demonstrate consistent quality, regulatory compliance, and post-market vigilance increasingly determines long-term positioning. Companies that proactively manage lifecycle planning, clinician engagement, and evidence synthesis will be best placed to influence standard-of-care decisions and to sustain clinician and patient trust.

Actionable and high-impact recommendations for manufacturers and stakeholders to strengthen supply resilience, evidence generation, clinician training, and patient access across channels

Industry leaders should prioritize a set of pragmatic, high-impact actions to preserve access, protect clinical trust, and create differentiated value propositions. First, enhance supply chain resilience by diversifying component sourcing and by establishing validated contingency suppliers to mitigate tariff-related disruptions and other interruptions. This operational flexibility should be complemented by a clear regulatory roadmap for qualifying alternative manufacturing sites and materials to avoid clinical supply gaps.

Second, invest in robust post-market evidence programs that emphasize safety, patient-reported outcomes, and real-world performance across diverse populations and care settings. Such evidence supports clinical adoption, informs payer conversations, and strengthens brand credibility. Third, accelerate clinician training initiatives with a focus on immediate postpartum insertion, adolescent care, and outpatient insertion protocols; training should be modular, accessible, and tied to competency validation to ensure consistent clinical outcomes.

Fourth, align distribution strategies with evolving patient access models by combining traditional hospital pharmacy channels with online pharmacy engagement and targeted retail pharmacy partnerships. Ensure that patient counseling materials and digital tools are consistent across channels to reduce confusion and to protect continuity of care. Finally, adopt transparent pricing and contracting approaches that allow purchasers to plan around tariff volatility and that facilitate long-term supply agreements. Executing these recommendations will require cross-functional coordination between clinical affairs, regulatory, supply chain, and commercial teams, but will materially strengthen market position and patient access.

A transparent explanation of research sources, evidence triangulation, and methodological steps used to synthesize clinical, regulatory, and supply chain insights for intrauterine devices

This analysis is grounded in a multi-source research approach that synthesizes peer-reviewed clinical literature, regulatory filings, device labeling, expert clinician interviews, and a systematic review of supply chain and policy developments. Clinical insights derive from randomized trials, observational cohorts, and longitudinal safety registries, which were evaluated for methodological rigor and relevance to contemporary practice. Regulatory materials, including approvals and post-market surveillance summaries, were examined to identify emerging compliance trends and safety signals that affect product life-cycle management.

Commercial and operational conclusions are informed by structured interviews with clinicians, procurement leaders, and distribution partners, as well as by a thematic review of publicly available guidance on procurement and insertion protocols. Trade policy and tariff impacts were analyzed through a combination of import/export databases, customs classifications, and industry-reported responses to tariff changes, with attention to operational mitigations and supply chain realignment strategies. The research also incorporated an assessment of clinician training program design and digital engagement models to evaluate how these elements influence uptake and sustained use.

Throughout the analysis, findings were triangulated across multiple sources to ensure consistency, and limitations were explicitly documented, including potential regional data gaps and variability in service delivery models. Where uncertainties exist, the report highlights areas that would benefit from primary data collection or targeted market testing to validate strategic assumptions.

A concise conclusion synthesizing how clinical advances, supply resilience, and targeted market strategies collectively determine future intrauterine device accessibility and positioning

The intrauterine device landscape is at an inflection point where clinical innovation, changing care delivery models, and trade policy considerations converge to create both opportunity and complexity. Technological refinements and expanding clinical acceptance, particularly for immediate postpartum and adolescent insertion, are increasing the role of these devices in comprehensive reproductive health strategies. At the same time, supply chain sensitivity to tariffs and component sourcing underscores the need for operational agility and closer alignment between manufacturing, regulatory, and procurement functions.

Successful stakeholders will be those that build resilient supply networks, invest in rigorous post-market evidence, and deploy targeted clinician training while embracing modern patient access channels. Regional heterogeneity requires tailored approaches that reflect local regulatory environments and payer structures, and segmentation by device type, distribution channel, end user, and usage duration offers a practical blueprint for matching product attributes to patient and provider needs.

In conclusion, the next phase of intrauterine device evolution will reward enterprises that combine clinical credibility with operational excellence and that adopt transparent, patient-centered access strategies. By executing on the recommendations outlined in this summary, organizations can strengthen their positioning and contribute to expanded, equitable access to effective long-acting contraception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intrauterine Devices Market, by Device Type

  • 8.1. Copper
  • 8.2. Hormonal

9. Intrauterine Devices Market, by Usage Duration

  • 9.1. Over Five Years
  • 9.2. Three To Five Years
  • 9.3. Under Three Years

10. Intrauterine Devices Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Intrauterine Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Intrauterine Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Intrauterine Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Intrauterine Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Intrauterine Devices Market

16. China Intrauterine Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Bayer AG
  • 17.7. BioFem Therapeutics, LLC
  • 17.8. Chongqing Zhifei Biological Products Co., Ltd.
  • 17.9. CooperCompanies, Inc.
  • 17.10. Gedeon Richter Plc.
  • 17.11. Medicines360, Inc.
  • 17.12. Meril Life Sciences Pvt. Ltd.
  • 17.13. Mona Lisa N.V.
  • 17.14. Mylan NV by Viatris Inc.
  • 17.15. Novartis AG
  • 17.16. Ocon Medical Ltd
  • 17.17. Pregna International Ltd.
  • 17.18. Prosan International BV
  • 17.19. Searchlight Pharma Inc.
  • 17.20. Shenzhen Salubris Pharmaceuticals Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INTRAUTERINE DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INTRAUTERINE DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COPPER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY OVER FIVE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY THREE TO FIVE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY UNDER THREE YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 89. GCC INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GCC INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 104. G7 INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. G7 INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 109. NATO INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NATO INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRAUTERINE DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA INTRAUTERINE DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY USAGE DURATION, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA INTRAUTERINE DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)